Helius Medical Technologies Inc Class A (HSDT) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Helius Medical Technologies Inc Class A $1.29, price $2.90, upside -55.5%, quality 22 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Helius Medical Technologies Inc Class A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $1.27 – $647,250 · fair‑value band $0.9690 – $1.62 · the $2.90 price screens above the $1.29 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Helius Medical Technologies Inc Class A in your weekly email
Every Wednesday you see whether Helius Medical Technologies Inc Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Solana Company operates as a listed digital asset treasury. The company enhances Solana tokens per share on the commercially viable blockchain for decentralized finance and consumer applications. It also focuses on neurological wellness.
Show more
Solana Company operates as a listed digital asset treasury. The company enhances Solana tokens per share on the commercially viable blockchain for decentralized finance and consumer applications. It also focuses on neurological wellness. In addition, the company offers Portable Neuromodulation Stimulator, a non-implantable medical device, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. Solana Company is headquartered in Newtown, Pennsylvania.
Stock analysis
Helius Medical Technologies Inc Class A (HSDT) currently trades at $2.90, while our model-based Fair Value estimate is $1.29, implying the stock looks roughly 124.5% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.9690 (bear) to $1.62 (bull), the price of $2.90 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 22/100 (below-average quality), in the Financial Services sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Helius Medical Technologies Inc Class A reported revenue of $6.0M in FY2025 versus $522K in FY2021, a compound +84.3%/yr. Reported net income was −$40.9M in FY2025.
Key figures
Market cap $94.6M · P/E ratio 0.0 · P/S ratio 9.86 · EPS (TTM) $375.66 · Return on equity −137% · Return on assets (EBIT) −156% · Operating margin −2,751% · Revenue (TTM) $9.6M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).
What moves the price
The share trades about 84% below its 52-week high and 128% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Financial Services peers we cover trades at −4% fair-value upside, at −55%, HSDT screens richer than that median.
Fair Value models
Bear $0.9690Fair Value $1.29Bull $1.62
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($274.80 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.25/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,057.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+97.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+55.5%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.6%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,129.5% (2020) → −351.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Helius Medical Technologies Inc Class A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Asset Management · 656 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score27 · Bottom 25%
Fair Value upside−55% · Bottom 25%
Growth and dividend
Revenue growth73% · Top 25%
Valuation Multiplesvs Asset Management median · lower = cheaper
P/E (TTM)0.0× · Cheapest 25%
P/B0.31× · Cheapest 25%
P/S (TTM)9.86× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 56
FUTURE (revenue growth)100· sector 21
PAST (return on equity)0· sector 22
HEALTH (low debt)0· sector 95
DIVIDEND (yield)0· sector 81
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Helius Medical Technologies Inc Class A Fair Value". https://www.fairvalue-calculator.com/stock/HSDT
Frequently asked questions
Is Helius Medical Technologies Inc Class A (HSDT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $1.29 versus a price of $2.90, about −55% upside (overvalued).
What is the fair value of HSDT?
Our model-based fair value for Helius Medical Technologies Inc Class A is $1.29 (as of Sep 23, 2026), built from audited fundamentals. The current price: $2.90.
What is the quality score of HSDT?
Helius Medical Technologies Inc Class A has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Helius Medical Technologies Inc Class A (HSDT)?
Our model-based price target is the fair value of $1.29 (as of Sep 23, 2026) from 2 valuation models. Cautious scenario $0.9690, optimistic scenario $1.62. It is a calculation from audited fundamentals, not an analyst target.
What is the Helius Medical Technologies Inc Class A stock forecast for 2026?
Our models put fair value at $1.29, about −55% upside versus a price of $2.90 (overvalued). Cautious scenario $0.9690, optimistic scenario $1.62. The calculation is refreshed regularly with new filings.
What is the revenue of Helius Medical Technologies Inc Class A (HSDT)?
Helius Medical Technologies Inc Class A reported trailing-twelve-month revenue of about $9.6M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Helius Medical Technologies Inc Class A (HSDT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Helius Medical Technologies Inc Class A it is $1.29 per share (as of Sep 23, 2026), against a price of $2.90. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Helius Medical Technologies Inc Class A stock overvalued or undervalued in 2026?
As of Sep 23, 2026, HSDT trades above its calculated fair value: price $2.90, fair value $1.29, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HSDT?
No. The price is what the market pays today ($2.90); the fair value is what the company's own numbers justify ($1.29). For Helius Medical Technologies Inc Class A the two are $1.61 per share apart. That gap is exactly why we show both numbers side by side.
How much is Helius Medical Technologies Inc Class A worth?
The market values Helius Medical Technologies Inc Class A at about $94.6M (market capitalisation, as of Sep 23, 2026). Per share that is $2.90; our models calculate a fair value of $1.29 per share.
What do the bullish and bearish scenarios say about HSDT?
Our models span a range for Helius Medical Technologies Inc Class A: cautious scenario $0.9690, base $1.29, optimistic $1.62 per share (as of Sep 23, 2026, price $2.90). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HSDT?
Helius Medical Technologies Inc Class A trades at a price-to-earnings ratio of 0.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $1.29 is built from several models across several years. Other multiples: P/B 0.3, P/S 9.9.
How solid is the balance sheet of Helius Medical Technologies Inc Class A (HSDT)?
Balance-sheet figures for Helius Medical Technologies Inc Class A (as of Sep 23, 2026): return on equity −137.4%. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is HSDT from its 52-week high?
Helius Medical Technologies Inc Class A trades at $2.90, about 84% below its 52-week high of $18.19 and 128% above the low of $1.27 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $1.29 is for.
Which stocks are comparable to Helius Medical Technologies Inc Class A?
From the same area (Financial Services) we also value Blackstone Inc, Brookfield Corporation, KKR & Co, Apollo Global Management, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Helius Medical Technologies Inc Class A stock attractive at the current price?
The data as of Sep 23, 2026: price $2.90, calculated fair value $1.29 (−55%), Quality Score 22/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HSDT calculated?
We run Helius Medical Technologies Inc Class A through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.29, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Helius Medical Technologies Inc Class A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Helius Medical Technologies Inc Class A (HSDT)?
The closing price on Sep 24, 2026 was $2.90. Our model-based fair value is $1.29, about −55% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Helius Medical Technologies Inc Class A right now?
The price sits above even our optimistic bull case ($1.62). The favourable scenario is already priced in. Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Key figures of Helius Medical Technologies Inc Class A
How large is the market capitalisation of Helius Medical Technologies Inc Class A (HSDT)?
The market capitalisation of Helius Medical Technologies Inc Class A is $94.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Helius Medical Technologies Inc Class A (HSDT)?
The price-to-sales ratio of Helius Medical Technologies Inc Class A is 9.86 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Helius Medical Technologies Inc Class A (HSDT)?
Earnings per share at Helius Medical Technologies Inc Class A are $375.66 (price ÷ EPS = P/E 0.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Helius Medical Technologies Inc Class A (HSDT)?
The return on equity (ROE) of Helius Medical Technologies Inc Class A is −137% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Helius Medical Technologies Inc Class A (HSDT)?
On an EBIT basis the return on assets of Helius Medical Technologies Inc Class A is −156% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Helius Medical Technologies Inc Class A (HSDT)?
The operating margin of Helius Medical Technologies Inc Class A is −2,751% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Helius Medical Technologies Inc Class A (HSDT)?
Revenue at Helius Medical Technologies Inc Class A is growing +72.9% versus a year earlier (3y avg +97.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Helius Medical Technologies Inc Class A (HSDT) generate?
The free cash flow of Helius Medical Technologies Inc Class A is −$61.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Helius Medical Technologies Inc Class A (HSDT) hold?
Helius Medical Technologies Inc Class A holds more cash than debt, $7.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Helius Medical Technologies Inc Class A in the live analysis
One click puts Helius Medical Technologies Inc Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026